# Vitamin B12 Deficiency

Confirm clinically meaningful cobalamin deficiency, treat neurologic or severe hematologic presentations urgently, and define whether dietary insufficiency, autoimmune gastritis, or intestinal malabsorption requires lifelong replacement and surveillance.

**Clinical question:** How should physicians confirm, treat, and prevent recurrence of vitamin B12 deficiency according to severity and cause?

Updated: 2026-08-24T18:33:22.708462+00:00

## What matters in practice
- Do not exclude vitamin B12 deficiency because anemia or macrocytosis is absent; neurologic and neuropsychiatric disease may be the presenting phenotype. [19][20]
- Use serum methylmalonic acid to support deficiency when serum B12 is low-normal or clinical suspicion persists; elevated methylmalonic acid supports cellular B12 deficiency. [3][9][12]
- Admit and initiate urgent intensive parenteral replacement for marked symptomatic anemia, pancytopenia, subacute combined spinal degeneration, or cognitive impairment/dementia attributed to B12 deficiency. [4]
- Test for anti-intrinsic-factor antibodies when B12 deficiency suggests autoimmune gastritis; intrinsic-factor failure produces persistent malabsorption and generally requires lifelong replacement. [1][8][12][24]
- High-dose oral cyanocobalamin can be effective, including in many malabsorptive states, but parenteral therapy is preferred initially for severe deficiency, neurologic disease, or unreliable oral adherence. [4][15][17]

## Identify presentations requiring immediate parenteral treatment

Severity determines whether diagnostic sampling can precede, but should not delay, replacement.

Hospitalize patients with pancytopenia, marked symptomatic anemia, or severe neurologic manifestations including subacute combined spinal degeneration, ataxia, dementia, or cognitive impairment, and begin urgent intensive cyanocobalamin or hydroxocobalamin therapy. Neurologic injury may be irreversible despite adequate replacement, making treatment urgency greater when gait dysfunction, weakness, sensory loss, or cognitive decline is progressive. [4][20]

Before the first dose when feasible, obtain CBC with hematocrit, reticulocyte count, serum B12, folate, and iron studies; collect confirmatory metabolite testing before replacement if the diagnosis is uncertain. Do not defer treatment in a patient with rapidly progressive neurologic or hematologic disease merely to complete testing. [15][13]

A megaloblastic anemia phenotype supports the diagnosis, but neurologic complications can occur without severe anemia. The inverse association between hemoglobin concentration and neurologic severity means a relatively preserved hemoglobin level does not provide reassurance in a patient with posterior-column symptoms, peripheral neuropathy, cognitive decline, or myelopathy. [20]
- Escalate urgently for progressive gait disturbance, incoordination, weakness, cognitive decline, or suspected myelopathy; these features can represent central or peripheral demyelinating disease from B12 deficiency. [2][18][22]
- Do not use response to empiric B12 alone as the sole diagnostic strategy when alternative causes of myelopathy, neuropathy, cytopenias, or cognitive decline remain plausible. B12 deficiency has heterogeneous presentations and is vulnerable to misattribution. [19][24]

*Clinical severity determines urgency and route of initial replacement. [4][15]*

| Presentation | Immediate action | Rationale |
| --- | --- | --- |
| Pancytopenia or marked symptomatic anemia | Hospitalize; initiate urgent intensive parenteral cyanocobalamin or hydroxocobalamin. [4] | Severe hematologic disease requires acute treatment. [4] |
| Subacute combined spinal degeneration, ataxia, dementia, or cognitive impairment | Hospitalize and give urgent intensive parenteral therapy; obtain baseline diagnostic specimens if this does not delay treatment. [4][15] | Neurologic deficits may become irreversible despite replacement. [4] |
| Mild-to-moderate manifestations or asymptomatic deficiency | Begin maintenance-level cyanocobalamin or hydroxocobalamin while establishing cause and feasibility of oral adherence. [4] | Maintenance replacement can prevent hematologic and neurologic complications. [4] |

## Confirm functional deficiency when the serum B12 result is equivocal

Interpret serum B12 in the clinical context rather than as an isolated exclusion test.

Start with serum B12 in patients with macrocytosis, anemia, neurologic symptoms, neuropsychiatric symptoms, or relevant nutritional and gastrointestinal risk factors. A low-normal B12 concentration can still reflect deficiency; an elevated serum methylmalonic acid supports functional cobalamin deficiency and is particularly useful when the initial B12 value does not match the clinical phenotype. [9][12][19]

Measure homocysteine as an adjunctive metabolic marker when available, but interpret it with methylmalonic acid rather than treating it as B12-specific: both homocysteine and methylmalonic acid are elevated in B12 deficiency. [3][19] Check folate concurrently because folate and B12 deficiency produce morphologically indistinguishable megaloblastic anemia, while neurologic injury is a key discriminator favoring B12 deficiency. [15][20]

If initial testing makes deficiency unlikely but symptoms or signs persist, repeat the original B12 test or obtain methylmalonic acid after 3 to 6 months. This interval applies to unresolved clinical suspicion rather than to progressive neurologic or hematologic illness, which warrants immediate reassessment and treatment. [12][13]
- Order CBC, reticulocyte count, folate, and iron studies with B12 evaluation to characterize cytopenias and coexisting nutritional deficiencies. [15]
- Use clinical response as supportive follow-up evidence, not as a substitute for evaluating other etiologies of cognitive decline, neuropathy, or spinal cord disease. [19][24]

### When to broaden beyond B12 deficiency

Persistent or progressive neurologic dysfunction despite biochemical correction should prompt reassessment for alternative central and peripheral nervous system disorders rather than repeated empiric dosing alone. B12-related neurologic syndromes overlap with myelopathy, neuropathy, autonomic dysfunction, optic atrophy, mood and behavioral changes, psychosis, memory impairment, and cognitive decline. [20]

*Biochemical and clinical findings that alter the next diagnostic step. [3][9][12][15][19]*

| Finding | Interpretation | Next step |
| --- | --- | --- |
| Low serum B12 with compatible anemia, neuropathy, or neuropsychiatric findings | Vitamin B12 deficiency is likely. [19] | Obtain baseline folate, iron studies, CBC, and reticulocyte count if not already collected; begin replacement according to severity. [15] |
| Low-normal serum B12 with compatible phenotype | Serum B12 alone may not exclude deficiency. [9][19] | Measure serum methylmalonic acid; elevation supports deficiency. [9] |
| Elevated methylmalonic acid and homocysteine | Pattern supports B12 deficiency. [3] | Identify dietary versus irreversible malabsorptive cause and institute replacement. [24] |
| Initial testing unlikely for deficiency but persistent symptoms at 3-6 months | Initial testing may require reassessment. [12] | Repeat the initial test or obtain methylmalonic acid. [12] |

## Separate reversible dietary deficiency from intrinsic-factor and ileal malabsorption

The cause determines duration, route, and intensity of recurrence prevention.

Classify the deficiency as dietary insufficiency, food-bound cobalamin malabsorption, autoimmune gastritis with intrinsic-factor failure, or terminal-ileal disease/resection. Clinically important deficiency is more likely to progress when intrinsic-factor-dependent absorption fails than when dietary intake alone is inadequate; most persistent causes evolve over years. [7][24]

Order anti-intrinsic-factor antibody testing in B12 deficiency when autoimmune gastritis is suspected. Autoimmune injury to oxyntic gastric parietal cells reduces intrinsic factor and produces B12 malabsorption; autoimmune gastritis is the disease process historically associated with pernicious anemia. [8][12][13]

Elicit prior terminal ileal resection, terminal ileitis, Crohn disease, and small-intestinal bacterial overgrowth. Patients with terminal ileal disease or resection are prone to B12 deficiency, and B12 replacement may be oral or parenteral depending on disease severity, absorption reliability, and response. [9][15] Deficiency may appear years after bariatric surgery because body stores delay clinical expression. [9]

Review diet and medication exposure. Strict vegan or vegetarian diets increase risk and justify maintenance-level replacement when deficiency risk is high. Long-term proton-pump inhibitor or histamine-2 receptor antagonist use is associated with lower B12 levels and should trigger review of ongoing indication, especially in older adults. [4][6][19]
- Treat autoimmune gastritis, intrinsic-factor deficiency, and substantial ileal loss as persistent causes requiring an ongoing replacement plan rather than a finite nutritional course. [1][8][24]
- For dietary deficiency, correct the dietary pattern and continue maintenance replacement; oral therapy is cost-effective for diet-related deficiency. [4][5]
- In patients with inflammatory bowel disease, screen for B12 deficiency when there is current or prior terminal ileal disease, terminal ileal resection, or risk of small-intestinal bacterial overgrowth. [9]

### Autoimmune gastritis and gastric surveillance

Document autoimmune gastritis explicitly rather than using anemia terminology alone, because the condition is irreversible and current guidance includes monitoring for gastric cancer in affected patients. Coordinate gastroenterology assessment for the surveillance strategy when autoimmune gastritis is identified. [11][13]

*Etiologic patterns that determine recurrence risk and long-term replacement. [1][4][6][8][9][12][24]*

| Etiologic branch | Key discriminator | Management implication |
| --- | --- | --- |
| Dietary insufficiency | Vegan or strict vegetarian dietary pattern without evidence of irreversible gastrointestinal disease. [4] | Use maintenance-level replacement and correct dietary intake; oral cyanocobalamin is cost-effective for diet-related deficiency. [4][5] |
| Autoimmune gastritis / intrinsic-factor failure | Positive anti-intrinsic-factor antibody testing in a compatible patient; parietal-cell injury reduces intrinsic factor. [8][12] | Plan lifelong B12 therapy and address autoimmune-gastritis complications, including gastric cancer monitoring. [1][11] |
| Terminal-ileal disease or resection | Crohn disease with terminal ileitis, terminal ileal resection, or small-intestinal bacterial overgrowth risk. [9] | Replace B12 orally or parenterally according to absorption, clinical severity, and response; anticipate recurrent deficiency. [9][15] |
| Food-bound cobalamin malabsorption or acid suppression exposure | Older age, chronic gastrointestinal illness, or long-term PPI/H2-receptor antagonist exposure. [4][6][7] | Review medication necessity and use a sustainable maintenance regimen with biochemical and clinical follow-up. [4][19] |

## Choose parenteral or high-dose oral replacement by severity, absorption, and adherence

Initial route should protect neurologic recovery while allowing a sustainable long-term regimen.

Use intramuscular replacement initially for severe cobalamin deficiency, especially when neurologic disease, marked anemia, pancytopenia, or malabsorption is present. Cyanocobalamin is commonly used in the United States; hydroxocobalamin is used more commonly in Europe and is particularly useful in malabsorptive states. [4][15][16]

For hydroxocobalamin treatment of B12-deficiency anemia, a cited regimen is 1 mg intramuscularly every other day for 5 to 10 doses, followed by 1 mg every 3 months for maintenance. Intensive regimens over approximately 1 month are recommended for severe hematologic or neurologic disease, followed by ongoing maintenance treatment. [4][16]

High-dose oral cyanocobalamin, including 1,000 mcg daily, can replenish B12 through passive absorption and has evidence of effectiveness comparable to intramuscular treatment in many patients, including those with Crohn disease and pernicious anemia. Select oral therapy only when the patient is clinically stable and can reliably adhere; choose parenteral therapy when oral adherence is doubtful or an irreversible malabsorptive cause is accompanied by severe disease. [1][4][15][17][21]

Avoid assuming that intranasal or sublingual preparations are interchangeable with established oral or intramuscular regimens; evidence and optimal dosing for those routes remain limited. [4] Cyanocobalamin is contraindicated in Leber hereditary optic neuropathy and is reported as contraindicated in renal insufficiency; confirm product-specific contraindications and select formulation accordingly. [5]
- Continue lifelong therapy for pernicious anemia or other persistent malabsorption. [1][24]
- Use maintenance-level replacement for asymptomatic people at high risk, including strict vegetarians, vegans, older adults, and patients with chronic gastrointestinal disease, to prevent potentially irreversible complications. [4]
- Pregnancy and lactation are not reasons to stop indicated replacement; ongoing or new B12 treatment for documented deficiency is mandatory and considered safe. [5]

### Selecting oral therapy

Oral therapy is a practical choice for dietary deficiency and for stable patients who prefer tablets and can adhere to daily dosing. In pernicious anemia, prospective treatment with oral cyanocobalamin 1,000 mcg daily has been studied over one year with serial B12, homocysteine, and methylmalonic acid assessments, supporting oral therapy as an option when adherence and follow-up are reliable. [5][21]

*Replacement route selection for vitamin B12 deficiency. [1][4][15][16][17][21]*

| Clinical setting | Preferred initial approach | Maintenance consideration |
| --- | --- | --- |
| Severe neurologic or hematologic deficiency | Urgent intensive intramuscular cyanocobalamin or hydroxocobalamin. [4][15] | Continue maintenance replacement after intensive treatment; use a lifelong regimen for persistent malabsorption. [1][4] |
| Hydroxocobalamin regimen | 1 mg IM every other day for 5-10 doses. [16] | Then 1 mg IM every 3 months. [16] |
| Stable dietary deficiency | High-dose oral cyanocobalamin is reasonable when adherence is reliable. [4][17] | Maintenance-level oral replacement plus dietary correction. [4][5] |
| Stable pernicious anemia or Crohn disease with reliable adherence | Consider oral cyanocobalamin 1,000 mcg daily as an alternative to IM therapy. [4][21] | Monitor clinical and biochemical response; maintain lifelong therapy when malabsorption persists. [1][21] |
| Poor adherence, cognitive impairment, frailty, or major social barriers | Favor intramuscular replacement. [13] | Establish a supervised or self-injection maintenance plan when feasible. [5][13] |

## Monitor clinical recovery, biochemical correction, and relapse risk

Follow-up must verify both correction and the adequacy of the long-term delivery plan.

At follow-up, assess the presenting phenotype directly: CBC and reticulocyte response for anemia or cytopenias; gait, proprioceptive symptoms, strength, paresthesias, and cognition for neurologic disease; and adherence to oral therapy or injection access. Follow-up is central because prevention of relapse depends on identifying the cause and maintaining effective replacement. [15][24]

For oral therapy in pernicious anemia, serial total plasma B12, homocysteine, and plasma methylmalonic acid have been used to assess biochemical response over one year. Persistent metabolite elevation, recurrent symptoms, or failure of hematologic recovery should prompt review of adherence, dosing route, ongoing malabsorption, coexisting folate or iron deficiency, and alternative diagnoses. [15][21][24]

Do not stop replacement solely because anemia corrects. Neurologic disease may coexist with minimal hematologic abnormality, and irreversible causes such as autoimmune gastritis, intrinsic-factor failure, and ileal resection require ongoing therapy to prevent recurrence. [1][20][24]
- Reassess the indication for chronic acid suppression in patients with B12 deficiency and ongoing PPI or H2-receptor antagonist exposure. [6][19]
- Teach self-injection when an ongoing parenteral regimen is selected and the patient can perform it safely; individualized injection frequency can improve feasibility. [5]
- Escalate persistent neurologic symptoms despite repletion for neurologic evaluation and reassessment of the differential diagnosis. [20][24]

*Follow-up targets after treatment initiation. [5][15][21][24]*

| Domain | What to reassess | Action if inadequate |
| --- | --- | --- |
| Hematologic response | CBC, hematocrit, and reticulocyte count. [15] | Reassess adherence, competing iron or folate deficiency, diagnosis, and adequacy of replacement route. [15][24] |
| Biochemical response | Serum B12; consider methylmalonic acid and homocysteine, particularly with oral treatment. [21] | Confirm adherence and consider parenteral replacement if oral delivery is unreliable or ineffective. [15][21] |
| Neurologic recovery | Gait, coordination, sensory symptoms, weakness, and cognition. [2][20] | Urgently reconsider alternative neurologic diagnoses if symptoms progress or do not fit the treatment response. [20][24] |
| Recurrence prevention | Whether the cause is dietary and reversible versus intrinsic-factor or ileal malabsorption. [1][9][24] | Continue lifelong therapy for persistent malabsorption; maintain dietary-risk supplementation when risk remains. [1][4] |

## References
1. Vitamin B12 Deficiency — www.nejm.org — https://www.nejm.org/doi/pdf/10.1056/nejmcp1113996
2. Neurologic Manifestations of Vitamin B12 Deficiency — www.nejm.org — https://www.nejm.org/doi/abs/10.1056/NEJMicm020588
3. AB0628 Vitamin B12, Homocysteine and Methylmalonic ... — ard.bmj.com — https://ard.bmj.com/content/74/Suppl_2/1109.1
4. Vitamin B12 deficiency - Management Approach | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/822/management-approach
5. Vitamin B12 — www.bmj.com — https://www.bmj.com/content/bmj/383/bmj-2022-071725.full.pdf
6. Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-019-53622-3
7. Vitamin B12 deficiency – A 21st century perspective — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1470211824019808
8. Have You Considered Pernicious Anemia? — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0736467922006485
9. Vitamin B12 Deficiency - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/vitamin-b12-deficiency
10. Pernicious anemia predominates among Mexican adults ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0034837626000082
11. Vitamin B12 deficiency in over 16s: diagnosis and ... — www.nice.org.uk — https://www.nice.org.uk/guidance/ng239
12. Guideline Vitamin B12 deficiency in over 16s — www.nice.org.uk — https://www.nice.org.uk/guidance/gid-ng10176/documents/draft-guideline
13. Recommendations | Vitamin B12 deficiency in over 16s: diagnosis and management | Guidance | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng239/chapter/recommendations
14. B12 and folate deficiency: Scenario: Management of anaemia — cks.nice.org.uk — https://cks.nice.org.uk/topics/anaemia-b12-folate-deficiency/management/management
15. Vitamin B12 (Cobalamin) - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=69909fe9549459423d462513
16. Hydroxocobalamin - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=69b0e1451a63f1308c5ed229
17. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency - Vidal‐Alaball, J - 2005 | Cochrane Library — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004655.pub2/references
18. Rare sensory and autonomic disturbances associated with ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0022510X09007424
19. The Many Faces of Cobalamin (Vitamin B12) Deficiency — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2542454819300335
20. Vitamin B12, folic acid, and the nervous system — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1474442206705981
21. Oral vitamin B12 supplementation in pernicious anemia — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0002916524004842
22. Biomarkers of Nutrition for Development (BOND): Vitamin B ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0022316622164266
23. Vitamin B12 deficiency and cognitive impairment — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S266645932500040X
24. How I treat cobalamin (vitamin B12) deficiency — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0006497120598431

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.